

Date: February 22, 2024

BSE Limited
P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Script Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) read with Para A of Part A of Schedule III to the Listing Regulations it is hereby informed that, the Hon’ble High Court of Delhi has decreed a Suit for a sum of Rs. 3 lakhs as damages and Rs. 2 lakhs as cost aggregating to Rs.5 Lakhs. There is no material impact on the financial, operations or other activities of the Company pursuant to this order.

The above decided case was related to Lifestar Pharma Private Limited, erstwhile subsidiary of the Company, which was earlier merged with the Company.

The detailed disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is enclosed as annexure I.

Request you to kindly take the above on record.

Thanking You,

Yours Faithfully,

For Mankind Pharma Limited

Pradeep Chugh
Company Secretary and Compliance Officer
Membership No. A18711

**Annexure I**

Disclosure as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Sr. No.	Details of event that needs to be provided	Details
1	Name of the authority	Hon'ble High Court of Delhi
2	Nature and details of the action(s) taken, initiated or order(s) passed	Hon'ble High Court of Delhi has decreed a Suit in favour of Hind Chemicals Limited (i.e. Plaintiff) for a sum of Rs. 3 lakhs as damages and Rs. 2 lakhs as cost aggregating to Rs.5 Lakhs.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	The Order of Hon'ble High Court of Delhi was signed on December 5, 2023, however the same has come to our knowledge on February 22, 2024.
4	Details of the violation(s)/contravention(s) committed or alleged to be committed	<p>The suit was filed by the Plaintiff in 2006 under Section 134 of the Trade Marks Act, 1999, in relation to the Plaintiff's mark 'SU-MAG' and Company's (i.e. Defendant) mark 'GUDMAG' used in respect of pharmaceutical preparations in Class 5, wherein Hon'ble High Court has identified that the packaging of the above pharmaceutical preparations of Plaintiff's and the Defendant's have almost identical colour combination.</p> <p>The above decided case was related to Lifestar Pharma Private Limited, erstwhile subsidiary of the Company, which was earlier merged with the Company.</p>
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible and reason for delay submission	<p>There is no material impact on the financial, operations or other activities of the Company as the Company had already stopped using the mark 'GUDMAG' since 2006.</p> <p>Due to an unintentional oversight at the external Counsel's end who was handling the matter, the Company was informed of and provided with the copy of the order on 22.02.2024.</p> <p>It's important to emphasize that the Company maintains a consistent practice of disclosing all material information within the prescribed timelines. The delay was due to an unintentional oversight on part of the external Counsel's end, being the sole reason for the above delay.</p>

MANKIND PHARMA LIMITED